Targeting the cMET pathway augments radiation response without adverse effect on hearing in NF2 schwannoma models [Medical Sciences]

Neurofibromatosis type II (NF2) is a disease that needs new solutions. Vestibular schwannoma (VS) growth causes progressive hearing loss, and the standard treatment, including surgery and radiotherapy, can further damage the nerve. There is an urgent need to identify an adjunct therapy that, by enhancing the efficacy of radiation, can...

http://ift.tt/2HPl3Rb